“Collagen market set to grow to $6bn by 2024” says new Visiongain report

08 April 2019
Pharma

Visiongain has launched a new pharma report Collagen Market Forecast 2019-2029: Revenue Prospects for Source, Product, and Application.

Currently, collagen has become in demand ingredient towards healthy foods development. Collagen productions in the body decline with age and bad diet. As collagen injection is not a preference to most people, the best way to gain collagen is through diet. Consequently, collagen has been blended together in a variety of foods and beverages products. Furthermore, it has been applied as protein dietary supplements, carriers in the meat processing, edible film and coatings of products, and food additive to enhance products’ quality.

The lead analyst of the report commented "Demand for premium grade collagen for surgical procedures, wound dressing, and drug delivery mechanisms is expected to drive the market within the forecast period. Marine collagen is expected to grow at a fast pace in the forecast period. Marine collagens are regarded as superior collagens as they are absorbed much more efficiently into the body. The market in the Asia Pacific is expected to register comparatively faster growth in terms of revenue over the next 10 years and this is attributed to increasing demand for beauty products and health supplements in the region."

Leading companies featured in the report include Advanced BioMatrix, Inc., Collagen Matrix, Collagen Solution Plc, Cologenesis HealthCare Pvt. Ltd., CONNOILS LLC, Croda International Plc., JBS S.A., Koninklijke DSM N.V., and other companies.

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongain.com or call her on +44 (0) 20 7549 9987.

About Visiongain
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

“Oncology remains the largest disease area in the pharmaceutical business. The oncology market is dominated by big pharma companies and high price labels” says Visiongain report

Although price is still the most important competitive advantage for a biosimilar company, current discount rates are not enough to automatically convince the key stakeholders of a biosimilar’s value.

10 September 2019

Read

“Anti-Infective Agents market set to grow to $141bn by 2024” says new Visiongain report

The global anti-infective agents market is one that is driven by innovation. This is vital for maintaining the rich pipeline of anti-infective agents seen in the market today.

09 September 2019

Read

“Global thyroid gland disorder treatment market is anticipated to grow at a lucrative CAGR of 3.6% and anticipated to reach USD 3.21 Billion by 2029”, says Visiongain report.

Thyroid disease is one of today’s most prevalent hormonal illnesses. Hyperthyroidism, hypothyroidism, and thyroid nodules are the most common thyroid gland disorders.

05 September 2019

Read

“Global somatostatin analogs market is anticipated to grow at a lucrative CAGR of 5.3% and anticipated to reach USD 4.78 Bn by 2029”, says Visiongain report.

Somatostatin was used to diagnose gastrointestinal tract tumors and acromegaly in the clinical environment.

05 September 2019

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever